BeOne Medicinces’ treatment of hepatocellular carcinoma was granted orphan designation by the FDA, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch
- Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
- BeOne Medicines downgraded to Hold from Buy at Jefferies
- BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
- Zymeworks, Royalty Pharma enter $250M royalty-backed note financing